2024
Costs of care during chimeric antigen receptor T-cell therapy in relapsed or refractory B-cell lymphomas
Di M, Potnis K, Long J, Isufi I, Foss F, Seropian S, Gross C, Huntington S. Costs of care during chimeric antigen receptor T-cell therapy in relapsed or refractory B-cell lymphomas. JNCI Cancer Spectrum 2024, 8: pkae059. PMID: 39115391, PMCID: PMC11340641, DOI: 10.1093/jncics/pkae059.Peer-Reviewed Original ResearchChimeric antigen receptor T-cell therapyB-cell lymphomaRelapsed/refractory B-cell lymphomaT-cell therapyCAR-T administrationCAR-T productsMedian total costCommercially insured patientsReal-world costsMedian costOut-of-pocket copaymentsCost of careLymphomaMonthly costTherapyPatientsProduct acquisitionFinancial outcomesHigher upfront cost
2023
Efficacy of CD19 directed therapies in patients with relapsed or refractory large b-cell lymphoma relapsing after CD19 directed chimeric antigen receptor T-cell therapy
Iqbal M, Jagadeesh D, Chavez J, Khurana A, Rosenthal A, Craver E, Epperla N, Li Z, Isufi I, Awan F, Dholaria B, Maakaron J, Sandoval-Sus J, Mishra R, Saha A, Annunzio K, Bhaskar S, Sumransub N, Fijalka A, Ivanov S, Lin Y, Kharfan-Dabaja M. Efficacy of CD19 directed therapies in patients with relapsed or refractory large b-cell lymphoma relapsing after CD19 directed chimeric antigen receptor T-cell therapy. Bone Marrow Transplantation 2023, 59: 211-216. PMID: 37973893, DOI: 10.1038/s41409-023-02148-4.Peer-Reviewed Original ResearchCAR-T therapyChimeric antigen receptor T-cell therapyT-cell therapyR LBCLT therapyMedian numberResponse rateCAR-T infusionEfficacy of CD19Limited clinical activityComplete response rateCAR-T productsDuration of responseOverall response rateMulti-center studyReal-world studyMedian followR diseaseMedian durationSystemic therapyMedian timeLoncastuximab tesirineAxicabtagene ciloleucelCD19-CARClinical activity